Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Prague – page 86

1 217 clinical trials in Prague, Czechia across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Prague at a glance
1 217
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 217 trials in Prague

Open in trial search

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on Long-term Safety and Effectiveness of NMRA-335140 for Patients with Major Depressive Disorder

Not recruiting
InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

Not recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dextrose Bp
  • Sponsor:AstraZeneca AB

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Iqvia Biotech Limited

Bladder cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Tremelimumab, and Chemotherapy in Patients with Advanced Bladder or Urinary System Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Prophylaxis against transplant rejection

Not recruiting

Study Comparing Tacrolimus Levels in Children with Organ Transplants Switching from Prograf to Advagraf

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Tacrolimus
  • Sponsor:Astellas Pharma Europe Limited

Atypical haemolytic uraemic syndrome

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Czechia

The busiest research cities in the country

All 158 cities in Czechia

Clinical research in Prague

What the registry says about research in the country

01 Cardiology & Metabolic Disorders

Innovative research focusing on TTR amyloidosis and heart disease treatments, alongside studies investigating hypertriglyceridemia management with novel therapeutics.

  • Heart Disease Management
  • Metabolic Disorders
  • Cardiovascular Prevention

Multiple trials evaluating new therapeutic approaches for heart failure prevention and treatment.

02 Oncology Research

Comprehensive studies in prostate cancer and multiple myeloma, with particular focus on metastatic conditions and novel treatment combinations.

  • Metastatic Cancer Treatments
  • Gastric Cancer Therapies
  • Blood Cancer Research

Advanced trials comparing innovative therapies against standard treatments in various cancer types.

03 Immunology & Vaccines

Extensive vaccine development programs including meningococcal and chickenpox vaccines, alongside studies in immune system disorders.

  • Pediatric Vaccines
  • Immune System Disorders
  • Preventive Medicine

Focus on immunogenicity and safety in various age groups from infants to adults.

04 Respiratory & Inflammatory Conditions

Research into chronic rhinosinusitis and COPD, along with studies on inflammatory bowel conditions.

  • Respiratory Disease Management
  • Inflammatory Conditions
  • Autoimmune Disorders

Evaluating new therapeutic approaches for chronic respiratory and inflammatory conditions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.